StockWatch
·

E.I.D.-PARRY (INDIA) LTD.

BSE: 500125

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
911.47
+21.2%-4.9%
Expenditure
939.20
+11.4%+8.5%
Net Profit
-22.48
+74.8%+92.1%
OPM %
-2.77%
+6.37pp+50.54pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-503.31-82.43338.45759.331.2KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

EID Parry Q2: Consolidated PAT Falls ~40% YoY to ₹253 Cr as Margins Compress

crop protection · fertiliser demand · margin compression

ResultsQ2 FY2713 Nov 20263 minFMCG

Profit Pressure Deepens—Watch for CPG Turnaround Progress

EID Parry · profit decline · CPG turnaround

Result previewQ2 FY2709 Nov 20263 minFMCG

PAT crumbles; restructuring cost masks strategy

restructuring · PAT miss · CPG margin

Result verdictFollow-upQ1 FY2719 Aug 20266 minFMCG
Latest
Board Meeting13 Nov, 3:02 pm

EID Parry Q2: Consolidated PAT Falls ~40% YoY to ₹253 Cr as Margins Compress

EID Parry's consolidated (primary) PAT attributable to owners fell ~40% YoY to ₹252.86 Cr from ₹424.41 Cr in Q2 FY26, even as group revenue dipped ~3.5% YoY to ₹11,219.70 Cr — a second straight quarter of YoY earnings weakness, as flagged in our pre-result preview. Sequentially both metrics jumped sharply (PAT +79% QoQ, revenue +24% QoQ) on the seasonal Kharif-season ramp in the Coromandel nutrient and allied business (₹9,042 Cr segment revenue, ₹745.90 Cr segment PBIT) — this QoQ strength is a seasonality artifact typical of the agri-input cycle, not a turnaround signal, and the YoY decline remains the operative story. No exceptional items hit either statement this quarter, so both prints are clean like-for-like comparisons. Margins compressed on a YoY basis: net margin (owners'-PAT basis) fell to ~2.25% from ~3.65% a year ago, though it improved from ~1.57% in Q1 FY27. Our own EBITDA-margin estimate from the filing works out to ~8.8%, down from ~10.3% YoY but up from Q1's ~8.3%. Beyond the dominant nutrient/crop-protection businesses, two standalone drag segments remain relevant: Consumer Products (CPG), whose loss widened to ₹24.48 Cr this quarter from ₹11.98 Cr in Q1 FY27 (though narrower than ₹26.93 Cr a year ago), and Nutraceuticals, which posted a ~10.9% margin (₹7.67 Cr profit on ₹70.10 Cr revenue) — below the 12-15% steady-state band management flagged on the August 2026 call. There is no verified external analyst consensus for this specific quarter (coverage is thin — the preview noted a single-analyst Buy rating with a recently cut FY27 target), so the cleanest yardstick is our own pre-result preview, which modeled consolidated revenue of ₹8,900-9,100 Cr, PAT of ₹100-140 Cr and an 8-9% EBITDA margin. The actual print beat that range decisively on revenue (+23-26% above the top end) and PAT (nearly double the top end), while the margin assumption landed almost exactly in the money (~8.8% vs 8-9% guided) — indicating the preview had under-anchored growth to Q1's seasonally soft base rather than Q2's agri-season strength. Against management's own prior framing from the last call: Nutraceuticals remains below its targeted margin band, and CPG shows no sequential progress toward the 4-5-quarter breakeven path (the loss widened, not narrowed, versus Q1); management gave no formal FY27 revenue/PAT guidance, consistent with the prior call, so that specific angle is unresolved on record. No management press release text was available to quote for this filing. Subsequent to the quarter, the Board approved a slump sale of the Sivagangai Distillery Unit on a going-concern basis (Nov 13, 2026), a non-adjusting event with no impact on these numbers; separately, standalone's year-ago quarter carried a ₹352.23 Cr one-off impairment tied to the Parry Sugars Refinery India (PSRIPL) closure that is absent this quarter and absent at the consolidated level throughout — which is why standalone's YoY narrative (loss narrowing to ₹22.49 Cr from ₹285.62 Cr) looks far better than the consolidated one. Going into Q3 FY27, the markers are whether CPG's loss actually starts narrowing toward its multi-quarter breakeven target, whether Nutraceuticals closes the gap to its 12-15% margin band, and whether the ₹100 Cr Jaggery capacity (guided online roughly six months from the August 2026 call, i.e. around February 2027) comes on stream as planned.

13 Nov 2026, 03:02 pm

Corporate Events

Board MeetingEIDPARRY
2026
13Nov

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingEIDPARRY
2026
12Aug

Board Meeting

The 51st Annual General Meeting ("AGM") of the Company will …

BSE Filing ↗
Board MeetingEIDPARRY
2026
26May

Board Meeting

The board meeting is scheduled to consider and approve the a…

BSE Filing ↗
Board MeetingEIDPARRY
2026
12Feb

Board Meeting

Consideration of unaudited financial results of the company …

BSE Filing ↗
Board MeetingEIDPARRY
2025
11Nov

Board Meeting

consider and approve The Unaudited financial results

BSE Filing ↗
Board MeetingEIDPARRY
2025
6Aug

Board Meeting

Consideration of Unaudited Financial Results for the quarter…

BSE Filing ↗
Board MeetingEIDPARRY
2025
27May

Board Meeting

Consider and approve the audited Standalone and Consolidated…

BSE Filing ↗
Board MeetingEIDPARRY
2024
14Nov

Board Meeting

Consider and approve

BSE Filing ↗
Board MeetingEIDPARRY
2024
24May

Board Meeting

Consider and approve the audited Standalone and Consolidated…

BSE Filing ↗
Board MeetingEIDPARRY
2024
6Feb

Board Meeting

Consider and approve financial results for Quarter and 9 mon…

BSE Filing ↗
DividendEIDPARRY
2023
21Nov

₹4 / share

BSE Filing ↗
Board MeetingEIDPARRY
2023
8Nov

Board Meeting

consider and approve update on dividend

BSE Filing ↗
Board MeetingEIDPARRY
2023
9Aug

Board Meeting

Approval of Unaudited Financial Results for the quarter ende…

BSE Filing ↗